TENX

Business Context and Reporting Period

Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended January 31, 2007 (Nine months ended January 31, 2007).
Business Stage: Development stage company focused on perfluorocarbon-based medical products, primarily "Oxycyte" (a synthetic blood substitute) and "Fluorovent" (an oxygen exchange fluid). The company also pursues a glucose biosensor implant.
Going Concern: The filing explicitly states substantial doubt exists regarding the company's ability to continue as a going concern due to an accumulated deficit of approximately $30 million and a lack of working capital to fund operations.

Key Financial Metrics

Note: The company has no revenue. Expenses are driven by Research & Development (R&D) and General & Administrative (G&A) costs, alongside significant interest expense due to debt financing.

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss for the nine months ended January 31, 2007, decreased to $2.30 million from $3.15 million in the prior year period. This was primarily due to a reduction in total expenses of approximately $842,000.
• R&D Expenses: R&D expenses dropped significantly to $567,917 (nine months 2007) from $957,897 (nine months 2006). Phase II clinical trial expenses were $50,018 compared to $292,317 in the prior year, attributed to a shortage of working capital.
• G&A Expenses: G&A expenses decreased to $818,952 from $1,004,926. Management temporarily ceased operations and laid off employees in October 2006 to conserve resources, though some were rehired in November 2006.
• Interest Expense: Interest expense decreased by $266,211 year-over-year due to significant convertible debt conversions that occurred in the previous fiscal year.
• Liquidity: Cash and cash equivalents increased from $382 at the end of the prior fiscal year (April 30, 2006) to $22,098 as of January 31, 2007, driven by financing activities.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Guidance

The company provides no specific financial guidance. Management estimates an additional $8,000,000 is required to complete Phase II clinical trials for Oxycyte. The company states it needs financing immediately to cover administrative expenses and ongoing testing. Without additional funding, the company may be forced to cease operations.

Management Commentary

Management is actively seeking equity and/or debt financing. Enrollment in the Phase II orthopedic surgery trial has been temporarily halted due to slow patient enrollment and resource constraints. A Phase II trial for sickle cell anemia is on hold pending FDA protocol changes.

Risks and Contingencies

• Going Concern: The independent auditor is expected to include an explanatory paragraph regarding the uncertainty of the company's ability to continue as a going concern.
• Capital Shortage: The company has negative working capital of $352,597 and insufficient funds to operate through the fiscal year.
• Regulatory Delays: Clinical trials are subject to FDA approval and protocol changes, which have already caused delays in the sickle cell anemia study.

Unusual Items

• Non-Cash Financing: Significant non-cash transactions occurred, including the issuance of stock to pay off $268,071 of convertible debentures and the issuance of warrants valued at over $500,000 as discounts on notes payable.
• Related Party Transactions: The company paid a specialty contract manufacturer (in which an officer is a minority shareholder) for manufacturing services and has outstanding payables to directors and shareholders.

Investor Verification Checklist

• Capital Sufficiency: Verify if the company has secured the immediate financing required to avoid ceasing operations, given the $22,098 cash balance and negative working capital.
• Debt Structure: Review the terms of the new notes payable (interest rates up to 18% and significant original issue discounts) and the impact of warrant issuance on future dilution.
• Clinical Trial Status: Confirm the current status of the Phase II Oxycyte trials, specifically the reasons for the hold on the orthopedic study and the timeline for the sickle cell anemia protocol changes.
• Going Concern Opinion: Review the most recent audit report to confirm the auditor's stance on the company's ability to continue as a going concern.
• Related Party Payables: Assess the risk associated with the $64,000 payable to directors and $81,000 payable to shareholders.